Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-PET and mpMRI in High-risk Prostate Cancer
NCT06565247Phase 3Recruiting
- Sponsor
- Region Västerbotten
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of radelumin in prostate cancer (PCa), sponsored by Region Västerbotten. Started Oct 2024; status: recruiting.
02
Drugs
radelumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06565247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565247.